Remote‐Controllable Immune‐Priming Spot Formation Via Nanocomplexed Hydrogel‐Assisted Histotripsy: Immunoasis
Advanced Materials · 2026
DOI: 10.1002/adma.202518245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Sung Hoon Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Hydrogels. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and ICT, South Korea, Ministry of Trade, Industry and Energy, Korean National Police Agency.
Abstract (Originalsprache)
Immunotherapy, which harnesses the immune system to eliminate cancer cells, offers durable, and specific responses. However, many tumors exhibit “immune deserts” — immunosuppressive microenvironments with low T cell infiltration due to the dominance of suppressive myeloid cells and limited inflammatory cues. Cancer vaccines combining tumor antigens and adjuvants can potentially convert these immune deserts into immune‐active lesions. Yet, systemic administration often leads to adverse effects such as cytokine storms and off‐target immune activation. To address this, we propose “ Immunoasis ”, a spatiotemporally controllable immunotherapeutic system. This platform integrates injectable, adjuvant‐loaded hydrogels with externally triggered boiling histotripsy. The hydrogel enables prolonged local retention of immunostimulatory payloads, while histotripsy disrupts tumor tissues and induces in situ conversion of the gel into nanocomplexes enriched with antigens and adjuvants. This localized activation enhances antigen presentation and promotes T cell recruitment at the tumor site. The tunable nature of the ultrasound stimulus provides flexible treatment scheduling and supports personalized cancer therapy. By establishing immune‐priming niches within the tumor, Immunoasis effectively transforms immune deserts into immune‐responsive microenvironments, enhancing antitumor immunity and improving therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
- Bionics Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
- Korea Institute of Science and Technology (KIST) School, University of Science and Technology (UST), Seoul, Republic of Korea.
- Department of Biomedical Engineering, Korea University, Seoul, Republic of Korea.
- Chemical and Biological Integrative Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
- KHU-KIST Department of Converging Science and Technology, Kyung Hee University, Seoul, Republic of Korea.
ORCID-Profile: Young-Min Kim
Förderung
- Ministry of Science and ICT, South Korea
- Ministry of Trade, Industry and Energy
- Korean National Police Agency
- Korea Institute of Science and Technology
- Ministry of Education
Zitieren
APA
Kim, S. H., Choi, W., Kim, Y., Kim, H., Jeong, G. W., Park, H., Youn, I., Park, Y., Han, S., & Kim, Y. M. (2026). Remote‐Controllable Immune‐Priming Spot Formation Via Nanocomplexed Hydrogel‐Assisted Histotripsy: Immunoasis. Advanced Materials. https://doi.org/10.1002/adma.202518245
Vancouver
Kim SH, Choi W, Kim Y, Kim H, Jeong GW, Park H, et al. Remote‐Controllable Immune‐Priming Spot Formation Via Nanocomplexed Hydrogel‐Assisted Histotripsy: Immunoasis. Advanced Materials. 2026. doi:10.1002/adma.202518245
BibTeX
@article{Kim2026,
author = {Kim, Sung Hoon and Choi, Wonseok and Kim, Yurim and Kim, Hyeongmin and Jeong, Gu Won and Park, Hyewon and Youn, Inchan and Park, Yoon and Han, Sungmin and Kim, Young-Min},
title = {Remote‐Controllable Immune‐Priming Spot Formation Via Nanocomplexed Hydrogel‐Assisted Histotripsy: Immunoasis},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202518245}
}
EUVIMED